Cargando…

Standard Versus Hypofractionated Radiation Therapy for Bladder Cancer: New Insights, but Questions Remain

Detalles Bibliográficos
Autores principales:	Baumann, Brian C., Sargos, Paul, Efstathiou, Jason A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759471/ https://www.ncbi.nlm.nih.gov/pubmed/34348106 http://dx.doi.org/10.1016/j.ijrobp.2021.04.048

Ejemplares similares

The Rationale for Post-Operative Radiation in Localized Bladder Cancer
por: Baumann, Brian C., et al.
Publicado: (2017)

Prostate cancer and hypofractionation: really a new standard of care?
por: Carrie, Christian, et al.
Publicado: (2016)

A practical approach to bladder preservation with hypofractionated radiotherapy for localised muscle-invasive bladder cancer
por: Portner, R., et al.
Publicado: (2021)

Hypofractionated Postmastectomy Radiation Therapy
por: Sayan, Mutlay, et al.
Publicado: (2020)

Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-Forward
por: Krug, David, et al.
Publicado: (2021)

Extreme hypofractionation in radiation therapy for patients with early breast cancer: what is the optimal technique?
por: Chin, Yaw Sinn
Publicado: (2022)

Early death in pediatric cancer: remaining questions and next steps
por: Furutani, Elissa, et al.
Publicado: (2017)

Combined-modality hypofractionated radiotherapy for elderly patients with glioblastoma: setting a new standard
por: Vellayappan, Balamurugan A, et al.
Publicado: (2017)

Two years of pandemic: A wealth of data and many remaining questions
por: Hamilton, Sara, et al.
Publicado: (2022)

Arterial Lymphatics in Atherosclerosis: Old Questions, New Insights, and Remaining Challenges
por: Csányi, Gábor, et al.
Publicado: (2019)

Extracorporeal membrane oxygenation for COVID-19: Some answers and a remaining question
por: Laverdure, Florent, et al.
Publicado: (2022)

Immunotherapy and Radiation – A New Combined Treatment Approach for Bladder Cancer?
por: Buchwald, Zachary S., et al.
Publicado: (2015)

Clinical comparison of brachytherapy versus hypofractionated external beam radiation versus standard fractionation external beam radiation for non-melanomatous skin cancers
por: Haseltine, Justin M, et al.
Publicado: (2016)

Hypofractionated Radiation Therapy for Large Brain Metastases
por: Masucci, Giuseppina Laura
Publicado: (2018)

Editorial: Bladder Cancer – A Cinderella Cancer: Advances and Remaining Research Questions
por: Van Hemelrijck, Mieke, et al.
Publicado: (2020)

Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider?
por: Sargos, Paul, et al.
Publicado: (2016)

Nutritional Ketosis in Parkinson’s Disease — a Review of Remaining Questions and Insights
por: Choi, Alexander, et al.
Publicado: (2021)

Comparing treatment uncertainty for ultra- vs. standard-hypofractionated breast radiation therapy based on in-vivo dosimetry
por: Fiagan, Yawo A.C., et al.
Publicado: (2022)

Mild Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
por: Matsui, Toshiaki, et al.
Publicado: (2020)

Vestibular Schwannoma: Results of Hypofractionated Stereotactic Radiation Therapy
por: Pialat, Pierre-Marie, et al.
Publicado: (2021)

Hypofractionated Radiation Therapy for Unresectable or Metastatic Sarcoma Lesions
por: Boyce-Fappiano, David, et al.
Publicado: (2022)

Moderate hypofractionation for prostate cancer
por: Arcangeli, Stefano, et al.
Publicado: (2017)

Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy
por: Young, Kristina H., et al.
Publicado: (2016)

Great Plagues of the Past and Remaining Questions
por: Cunha, Cheston B., et al.
Publicado: (2008)

Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment
por: Hafeez, Shaista, et al.
Publicado: (2017)

Hypofractionation trials and radiobiology of prostate cancer
por: Gulliford, Sarah, et al.
Publicado: (2017)

Cost‐containment in hypofractionated radiation therapy: a literature review
por: Hunter, Darren, et al.
Publicado: (2018)

AB013. Treatment of thymic oligometastastic or oligoprogressive lesions with hypofractionated radiation therapy or stereotactic body radiation therapy
por: Jackson, Christopher B., et al.
Publicado: (2022)

Tumour Movement in Proton Therapy: Solutions and Remaining Questions: A Review
por: De Ruysscher, Dirk, et al.
Publicado: (2015)

When Less is More: The Rising Tide of Hypofractionation
por: Aitken, K., et al.
Publicado: (2022)

Respirators versus medical masks: evidence accumulates but the jury remains out
por: Killingley, Ben
Publicado: (2011)

Remaining Questions about Clinical Variola Major
por: Lane, J. Michael
Publicado: (2011)

TASTE: To aspirate, or not to aspirate, remains a question
por: Elmahdy, Mahmoud Farouk
Publicado: (2014)

Hospital El Salvador: broader questions remain
por: Amaral, Arevalo, et al.
Publicado: (2021)

Liver failure—future challenges and remaining questions
por: Lemmer, Peter, et al.
Publicado: (2021)

The question of WGS’s clinical utility remains unanswered
por: Battke, Florian, et al.
Publicado: (2021)

Endoglin Targeting: Lessons Learned and Questions That Remain
por: Liu, Yingmiao, et al.
Publicado: (2020)

Hypofractionation: The standard for external beam breast irradiation
por: Brunt, Adrian Murray, et al.
Publicado: (2023)

Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas
por: Elhammali, Adnan, et al.
Publicado: (2015)

Hypofractionated stereotactic radiation therapy for recurrent glioblastoma: single institutional experience
por: Ciammella, Patrizia, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_8962u8lclid8osi328nqbqv1cg